AbbVie's Skyrizi Approved for Pediatric Psoriatic Disease
The US FDA has approved AbbVie's Skyrizi (risankizumab) for children aged six and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis. The approval is based on results from the phase 3 OptIMMize clinical trial program, expanding the drug’s usage to a younger demographic.
Tickers: $ABBV
Topics: clinical_trials pharmaceuticals psoriasis